ZYDUS LIFESCIENCES LIMITED

Kirti Ganorkar, a 29-year Sun Pharma veteran, will become Managing Director on September 1, 2025, succeeding founder Dilip Shanghvi who transitions to Executive Chairman.

Zydus Lifesciences has signed an exclusive licensing agreement with US-based Agenus Inc to commercialize the investigational cancer therapy combination of Botensilimab (BOT) and Balstilimab (BAL) in India and Sri Lanka.

DelveInsight's 2025 assessment reveals a robust sickle cell disease pipeline with 55+ companies developing 60+ therapeutic candidates across various clinical development stages.

Zydus MedTech has formed a strategic partnership with Brazil-based Braile Biomedica to exclusively commercialize Transcatheter Aortic Valve Implantation (TAVI) technology in Europe, India, and select markets.

Sentynl Therapeutics has published the first comprehensive clinical evidence for NULIBRY (fosdenopterin), showing statistically significant survival benefits in patients with Molybdenum Cofactor Deficiency Type A compared to untreated patients.

A Canadian population-based study found bevacizumab biosimilars Mvasi and Zirabev provided $6,379 CAD in annual cost savings per patient compared to originator Avastin while maintaining equivalent survival outcomes in metastatic colorectal cancer.

Zydus Lifesciences has received final USFDA approval to manufacture Ketoconazole Shampoo 2%, a generic equivalent of Nizoral Shampoo used to treat dandruff and fungal skin infections.

Zydus Lifesciences introduces ANVIMO (letermovir) in India, offering a breakthrough treatment for preventing Cytomegalovirus infection in stem cell and kidney transplant patients.

Zydus Lifesciences' Ahmedabad-based topical manufacturing facility successfully passed USFDA inspection with zero observations during a routine surveillance conducted February 10-14, 2025.

The FDA has granted Orphan Drug Designation to Zydus' Usnoflast for treating amyotrophic lateral sclerosis (ALS), a rare neurodegenerative disease.